pharma news today obesity drugs glp-1 october 2025 trends 2025: real-world data, patient outcomes & future therapies Chart: 1 in 8 Americans
Description
WHAT'S INSIDE?- GLP-1 Probiotic is formulated with the beneficial bacterial strains that help you produce more GLP-1, based on preclinical studies
Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62
Individuals should consult their clinicians regarding diagnosis or treatment decisions
Repatha (evolocumab) is a PCSK9 inhibitor that cuts LDL by ~60% when statins aren't enough
